Create Account | Sign In: Author or Forum

Search Symptoms

Category: Pharmacy | Surgery | Anesthesiology & Pain | Journal

Back to Journal Articles

Hydrocodone Schedule Change Affected Post-Op Opioid Rx

Last Updated: August 24, 2018.

Hydrocodone's change from schedule III to schedule II in 2014 was associated with an increase in the amount of opioids filled in the initial prescription after surgery, according to a study published online Aug. 22 in JAMA Surgery.

FRIDAY, Aug. 24, 2018 (HealthDay News) -- Hydrocodone's change from schedule III to schedule II in 2014 was associated with an increase in the amount of opioids filled in the initial prescription after surgery, according to a study published online Aug. 22 in JAMA Surgery.

Joe Habbouche, from the University of Michigan in Ann Arbor, and colleagues examined trends in the amount of postoperative opioids filled before and after the U.S. Drug Enforcement Administration moved hydrocodone-containing analgesics from schedule III to schedule II. Data were analyzed from 5,120 prescribers and 21,955 inpatients undergoing elective surgical procedures across 75 hospitals who filled an opioid prescription within 14 days of discharge to home.

The researchers found that the mean oral morphine equivalents (OMEs) filled in the initial opioid prescription increased by about 35 after the schedule change (β = 35.1; P < 0.01), which was equivalent to seven hydrocodone tablets (5 mg). Before and after the schedule change, there were no significant differences in the total OMEs filled during the 30-day postoperative period (β = 18.3; P = 0.55); the refill rate decreased significantly (β = −5.2 percent; P < 0.001).

"Opioid-related policies require close follow-up to identify and address early unintended effects given the multitude of competing factors that influence health care professional prescribing behaviors," the authors write.

Abstract/Full Text (subscription or payment may be required)


Previous: Breastfeeding Linked to Lower Risk of Stroke Post-Menopause Next: TNFi Not Linked to Increased Cancer Recurrence in RA Patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: